Akili Launches EndeavorRx® Expedition—A Direct-To-Consumer Product Registry

Digital medicine company Akili Interactive (Akili) launched the EndeavorRx® Expedition product registry. The registry will collect feedback from consumers (and their caregivers) using the EndeavorRx prescription digital therapeutic to improve attention among children ages 8 to 12 who are diagnosed with attention deficit/hyperactivity disorder. The goal is to determine the real-world effectiveness of EndeavorRx.

EndeavorRx is first and only prescription video game treatment cleared by the U.S. Food and Drug Administration (FDA). The registry is open to any consumer (and caregiver) prescribed EndeavorRx. It will collect data on user characteristics, usage patterns, and effectiveness. Data from the . . .